TuHURA Biosciences, Inc. Price & Performance (HURA)

TuHURA Biosciences has amended its agreement to acquire Kineta, pushing the closing deadline to June 30, 2025, and requiring a $20 million capital raise before completion. The revised terms include additional cash advances to Kineta, reflecting both companies' commitment to finalizing the merger amid ongoing biotech sector volatility.12

Sonavex has received FDA 510(k) clearance for its EchoMap device, which uses 3D ultrasound to provide real-time blood flow data for arteriovenous fistula monitoring. The innovation aims to improve patient outcomes by enabling more precise and immediate clinical decisions in vascular access management, marking a significant step in medical device development.3

CytoDyn has appointed Robert E. Hoffman as its new CFO, effective May 15, 2025, succeeding interim CFO Mitch Cohen. Hoffman brings extensive biotech leadership experience, including recent roles at Kintara Therapeutics. His appointment comes as CytoDyn focuses on strengthening its financial strategy and advancing its clinical pipeline.45